Limits...
Modified Pulsatilla decoction attenuates oxazolone-induced colitis in mice through suppression of inflammation and epithelial barrier disruption.

Wang X, Fan F, Cao Q - Mol Med Rep (2016)

Bottom Line: Assessment of clinical colitis and histological examination found that the administration of modified Pulsatilla decoction attenuated the severity of oxazolone‑induced colitis in mice.Measurement of cytokine concentration, western blotting and reverse transcription‑quantitative polymerase chain reaction demonstrated modified Pulsatilla decoction treatment significantly reduced the secretion of pro‑inflammatory cytokines and restored alterations in tight junction proteins in the colon tissues.Thus, the findings of the present study demonstrated that modified Pulsatilla decoction offers an effective therapeutic approach for the treatment of IBD and revealed the underlying mechanisms of action offered by modified Pulsatilla decoction.

View Article: PubMed Central - PubMed

Affiliation: Department of Gastroenterology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200062, P.R. China.

ABSTRACT
Inflammatory bowel diseases (IBDs) are chronic inflammatory gastrointestinal disorders caused by a dysregulated mucosal immune response and epithelial barrier disruption. Conventional treatment of IBD is currently limited to overcoming patient symptoms and is often associated with severe adverse effects from the drugs used. Modified Pulsatilla decoction has been used previously to treat ulcerative colitis (UC) in clinical practice in China, however, the underlying mechanism in the treatment of UC remains to be elucidated. In the present study, the efficiency and mechanisms of modified Pulsatilla decoction in the treatment of oxazolone‑induced colitis were investigated. Assessment of clinical colitis and histological examination found that the administration of modified Pulsatilla decoction attenuated the severity of oxazolone‑induced colitis in mice. Measurement of cytokine concentration, western blotting and reverse transcription‑quantitative polymerase chain reaction demonstrated modified Pulsatilla decoction treatment significantly reduced the secretion of pro‑inflammatory cytokines and restored alterations in tight junction proteins in the colon tissues. In addition, modified Pulsatilla decoction suppressed the activation of the nuclear factor‑κB signaling pathway. Thus, the findings of the present study demonstrated that modified Pulsatilla decoction offers an effective therapeutic approach for the treatment of IBD and revealed the underlying mechanisms of action offered by modified Pulsatilla decoction.

No MeSH data available.


Related in: MedlinePlus

Modified Pulsatilla decoction treatment inhibits the activation of the nuclear factor-κB signaling pathway. The expression of IκBα in the colon tissues of oxazolone-induced colitis mice treated with or without modified Pulsatilla decoction were detected using western blot analysis. Data are expressed as the mean ± standard deviation. **P<0.01 vs. the control group. IκBa, nuclear factor-κBα; PBS, phosphate-buffered saline; SASP, sulfasalazine; Con, control.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4940073&req=5

f4-mmr-14-02-1173: Modified Pulsatilla decoction treatment inhibits the activation of the nuclear factor-κB signaling pathway. The expression of IκBα in the colon tissues of oxazolone-induced colitis mice treated with or without modified Pulsatilla decoction were detected using western blot analysis. Data are expressed as the mean ± standard deviation. **P<0.01 vs. the control group. IκBa, nuclear factor-κBα; PBS, phosphate-buffered saline; SASP, sulfasalazine; Con, control.

Mentions: The nuclear transcription factor, NF-κB, is core in monitoring the development and progression of IBD by regulating the expression levels of a wide range of pro-inflammatory cytokines. IκBα is one member of a family of cellular proteins, which function to inhibit the NF-κB transcription factor. The stabilization of the IκB-α subunit in the cytoplasm indicates the NF-κB signaling has been inhibited (25). For further insight into the molecular mechanism underlying the therapeutic effects of modified Pulsatilla decoction in IBD, the present study detected the expression of IκBα in the colon tissues of mice treated with or without modified Pulsatilla decoction. As shown in Fig. 4, the expression of IκB-α was decreased in the colonic tissues of the oxazolone-induced colitis mice. However, stabilization of the IκB-α subunit in the colonic tissues of the modified Pulsatilla decoction- and SASP-treated mice was comparable to that of the normal mice. Therefore, modified Pulsatilla decoction inhibited the activation of the NF-κB signaling pathway, which contributed to its therapeutic effects on IBD.


Modified Pulsatilla decoction attenuates oxazolone-induced colitis in mice through suppression of inflammation and epithelial barrier disruption.

Wang X, Fan F, Cao Q - Mol Med Rep (2016)

Modified Pulsatilla decoction treatment inhibits the activation of the nuclear factor-κB signaling pathway. The expression of IκBα in the colon tissues of oxazolone-induced colitis mice treated with or without modified Pulsatilla decoction were detected using western blot analysis. Data are expressed as the mean ± standard deviation. **P<0.01 vs. the control group. IκBa, nuclear factor-κBα; PBS, phosphate-buffered saline; SASP, sulfasalazine; Con, control.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4940073&req=5

f4-mmr-14-02-1173: Modified Pulsatilla decoction treatment inhibits the activation of the nuclear factor-κB signaling pathway. The expression of IκBα in the colon tissues of oxazolone-induced colitis mice treated with or without modified Pulsatilla decoction were detected using western blot analysis. Data are expressed as the mean ± standard deviation. **P<0.01 vs. the control group. IκBa, nuclear factor-κBα; PBS, phosphate-buffered saline; SASP, sulfasalazine; Con, control.
Mentions: The nuclear transcription factor, NF-κB, is core in monitoring the development and progression of IBD by regulating the expression levels of a wide range of pro-inflammatory cytokines. IκBα is one member of a family of cellular proteins, which function to inhibit the NF-κB transcription factor. The stabilization of the IκB-α subunit in the cytoplasm indicates the NF-κB signaling has been inhibited (25). For further insight into the molecular mechanism underlying the therapeutic effects of modified Pulsatilla decoction in IBD, the present study detected the expression of IκBα in the colon tissues of mice treated with or without modified Pulsatilla decoction. As shown in Fig. 4, the expression of IκB-α was decreased in the colonic tissues of the oxazolone-induced colitis mice. However, stabilization of the IκB-α subunit in the colonic tissues of the modified Pulsatilla decoction- and SASP-treated mice was comparable to that of the normal mice. Therefore, modified Pulsatilla decoction inhibited the activation of the NF-κB signaling pathway, which contributed to its therapeutic effects on IBD.

Bottom Line: Assessment of clinical colitis and histological examination found that the administration of modified Pulsatilla decoction attenuated the severity of oxazolone‑induced colitis in mice.Measurement of cytokine concentration, western blotting and reverse transcription‑quantitative polymerase chain reaction demonstrated modified Pulsatilla decoction treatment significantly reduced the secretion of pro‑inflammatory cytokines and restored alterations in tight junction proteins in the colon tissues.Thus, the findings of the present study demonstrated that modified Pulsatilla decoction offers an effective therapeutic approach for the treatment of IBD and revealed the underlying mechanisms of action offered by modified Pulsatilla decoction.

View Article: PubMed Central - PubMed

Affiliation: Department of Gastroenterology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200062, P.R. China.

ABSTRACT
Inflammatory bowel diseases (IBDs) are chronic inflammatory gastrointestinal disorders caused by a dysregulated mucosal immune response and epithelial barrier disruption. Conventional treatment of IBD is currently limited to overcoming patient symptoms and is often associated with severe adverse effects from the drugs used. Modified Pulsatilla decoction has been used previously to treat ulcerative colitis (UC) in clinical practice in China, however, the underlying mechanism in the treatment of UC remains to be elucidated. In the present study, the efficiency and mechanisms of modified Pulsatilla decoction in the treatment of oxazolone‑induced colitis were investigated. Assessment of clinical colitis and histological examination found that the administration of modified Pulsatilla decoction attenuated the severity of oxazolone‑induced colitis in mice. Measurement of cytokine concentration, western blotting and reverse transcription‑quantitative polymerase chain reaction demonstrated modified Pulsatilla decoction treatment significantly reduced the secretion of pro‑inflammatory cytokines and restored alterations in tight junction proteins in the colon tissues. In addition, modified Pulsatilla decoction suppressed the activation of the nuclear factor‑κB signaling pathway. Thus, the findings of the present study demonstrated that modified Pulsatilla decoction offers an effective therapeutic approach for the treatment of IBD and revealed the underlying mechanisms of action offered by modified Pulsatilla decoction.

No MeSH data available.


Related in: MedlinePlus